Form 4: Director Jerrold Grossman Increases ADMA Biologics Stake

ADMA Biologics Director Jerrold B. Grossman acquired 6,400 shares of common stock in an open market transaction.

Summary

• Director Jerrold B. Grossman purchased 6,400 shares of ADMA Biologics common stock on May 27, 2026.
• The shares were acquired at a price of $7.91 per share.
• Following this transaction, the director's direct beneficial ownership increased to 520,284 shares.
• The reporting person maintains additional indirect holdings through various entities and family accounts.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as consistent insider buying often correlates with management's confidence in the company's strategic direction.

Positives

• Insider confidence is demonstrated by the director's open market purchase of company stock.
• The purchase reflects a commitment to the company's long-term value by a member of the board.

Negatives

• None identified in this filing.

Risks

• The reporting person's holdings are subject to market volatility and general equity investment risks.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this ownership disclosure.

Industry Context

StockSavvy.ai notes that insider buying is generally viewed as a positive signal by the market, suggesting that those with the most intimate knowledge of the company's pipeline and financial health believe the stock is undervalued or poised for growth.

Comparison to Industry Standards

• Insider purchases by board members are standard practice in the biotechnology sector to signal alignment with shareholder interests.
• The transaction size is consistent with typical director-level equity accumulation patterns in mid-cap biotech firms.

Related Party Transactions

• The reporting person is the managing member of Brookwood LLC, which holds 22,857 shares.
• The reporting person serves as investment trustee for the Jerrold Grossman 2019 Irrevocable Trust, which holds 31,381 shares.
• The reporting person is the President of Genesis Foundation Inc., which holds 38,294 shares.
• The reporting person's wife holds 175 shares.

Stakeholder Impact

• Shareholders may interpret the director's purchase as a vote of confidence in the company's current valuation and future prospects.

Next Steps

• Future vesting of 10,690 RSUs granted on February 9, 2026, scheduled for August 9, 2026, and February 9, 2027.

Key Dates

Keywords

ADMA Biologics, Insider Trading, Form 4, Director Purchase, Biotech, Equity Ownership